Glomerular 20-HETE, EETs, and TGF-β1 in diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 3, 2009, Pages

  Luo, Pengcheng ^a,b   Zhou, Yiqiang ^a   Chang, Hsin Hsin ^a   Zhang, Jie ^b   Seki, Tsugio ^a   Wang, Cong Yi ^a   Inscho, Edward W ^a   Wang, Mong Heng ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

CYP derived eicosanoids; Kidney; Streptozotocin

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ALBUMIN; CHOLESTEROL; CLOFIBRATE; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2J; CYTOCHROME P450 4A; EPOXYICOSATRIENOIC ACID; GLUCOSE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME SYNTHESIS; GLOMERULUS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERLIPIDEMIA; KIDNEY BLOOD FLOW; KIDNEY MASS; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

8,11,14-EICOSATRIENOIC ACID; ALKANE 1-MONOOXYGENASE; AMINO ACIDS; ANIMALS; CLOFIBRATE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; HYDROXYEICOSATETRAENOIC ACIDS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; KIDNEY; KIDNEY GLOMERULUS; MALE; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 66049095932     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90613.2008     Document Type: Article

References (43)

1. Al-Douahji M, Brugarolas J, Brown PA, Stehman-Breen CO, Alpers CE, Shankland SJ. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 56: 1691-1699, 1999. (Pubitemid 29518169)
2. Aldridge TC, Tugwood JD, Green S. Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 306: 473-479, 1995.
3. Chen H, Brahmbhatt S, Gupta A, Sharma AC. Duration of streptozotocin- induced diabetes differentially affects p38-mitogen-activated protein kinase (MAPK) phosphorylation in renal and vascular dysfunction. Cardiovasc Diabetol 4: 3, 2005. (Pubitemid 41460766)
4. Chen LL, Zhang JY, Wang BP. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul Pharmacol 44: 309-315, 2006.
5. Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR, Capdevila JH. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 277: 35105-35112, 2002.
6. Dahly-Vernon AJ, Sharma M, McCarthy ET, Savin VJ, Ledbetter SR, Roman RJ. Transforming growth factor-beta, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats. Hypertension 45: 643-648, 2005. (Pubitemid 40418360)
7. Danda RS, Habiba NM, Rincon-Choles H, Bhandari BK, Barnes JL, Abboud HE, Pergola PE. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 68: 2562-2571, 2005. (Pubitemid 43251001)
8. Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, Imig JD. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes Res 12: 1278-1289, 2004. (Pubitemid 41137472)
9. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43: 48-56, 2004.
10. Fogo AB. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl 75: S15-S21, 2000.
11. Fossati P, Prencipe L, Berti G. Enzymic creatinine assay: a new colorimetric method based on hydrogen peroxide measurement. Clin Chem 29: 1494-1496, 1983.
12. Hall JE. The kidney, hypertension, obesity. Hypertension 41: 625-633, 2003.
13. Huang H, Morisseau C, Wang J, Yang T, Falck JR, Hammock BD, Wang MH. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol 293: F342-F349, 2007. (Pubitemid 47345035)
14. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289: F496-F503, 2005.
15. Imig JD. Eicosanoids and renal vascular function in diseases. Clin Sci (Colch) 111: 21-34, 2006.
16. Ishizuka T, Ito O, Tan L, Ogawa S, Kohzuki M, Omata K, Takeuchi K, Ito S. Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney. Hypertens Res 26: 929-936, 2003. (Pubitemid 37508972)
17. Ito O, Roman RJ. Regulation of P-450 4A activity in the glomerulus of the rat. Am J Physiol Regul Integr Comp Physiol 276: R1749-R1757, 1999. (Pubitemid 29323541)
18. Lodha S, Dani D, Mehta R, Bhaskaran M, Reddy K, Ding G, Singhal PC. Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol Med 8: 830-840, 2002. (Pubitemid 36223136)
19. McCarthy ET, Sharma R, Sharma M. Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier. Kidney Int 67: 152-156, 2005. (Pubitemid 40019236)
20. McGowan T, McCue P, Sharma K. Diabetic nephropathy. Clin Lab Med 21: 111-146, 2001. (Pubitemid 32293566)
21. Muerhoff AS, Griffin KJ, Johnson EF. The peroxisome proliferator- activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. J Biol Chem 267: 19051-19053, 1992.
22. Natarajan R, Reddy MA. HETEs/EETs in renal glomerular and epithelial cell functions. Curr Opin Pharmacol 3: 198-203, 2003. (Pubitemid 36416559)
23. Nguyen X, Wang MH, Reddy KM, Falck JR, Schwartzman ML. Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol Regul Integr Comp Physiol 276: R1691-R1700, 1999. (Pubitemid 29323534)
24. Onso-Galicia M, Frohlich B, Roman RJ. Induction of P4504A activity improves pressure natriuresis in Dahl S rats. Hypertension 31: 232-236, 1998. (Pubitemid 28124721)
25. Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69: 1511-1517, 2006.
26. Roman RJ, Ma YH, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt- sensitive rats. Hypertension 21: 985-988, 1993. (Pubitemid 23166953)
27. Roopa BA, Loganath A, Singh K. The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium. Hum Reprod 18: 1809-1819, 2003. (Pubitemid 37107552)
28. Schiffer M, Bitzer M, Roberts IS, Kopp JB, Ten DP, Mundel P, Bottinger EP. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108: 807-816, 2001. (Pubitemid 32880291)
29. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996. (Pubitemid 26110260)
30. Sharma R, Khanna A, Sharma M, Savin VJ. Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 58: 131-136, 2000. (Pubitemid 30429857)
31. Spencer MW, Muhlfeld AS, Segerer S, Hudkins KL, Kirk E, LeBoeuf RC, Alpers CE. Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice. Am J Nephrol 24: 20-31, 2004. (Pubitemid 38250483)
32. Tryggvason K, Wartiovaara J. Molecular basis of glomerular perms-electivity. Curr Opin Nephrol Hypertens 10: 543-549, 2001.
33. Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 11: 71-79, 2000. (Pubitemid 30020428)
34. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 42: 594-599, 2003. (Pubitemid 37237359)
35. Wang MH. Renal cytochrome P450-derived eicosanoids and hypertension. Curr Hyperten Rev 2: 227-236, 2006.
36. Williams JM, Sharma M, Anjaiahh S, Falck JR, Roman RJ. Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier. Am J Physiol Renal Physiol 293: F501-F505, 2007. (Pubitemid 47358120)
37. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 8: 952-959, 2007.
38. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818, 1993. (Pubitemid 23069947)
39. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108: 261-268, 2001. (Pubitemid 32656250)
40. Zhao X, Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 4: 73-84, 2003. (Pubitemid 36131685)
41. Zhou Y, Huang H, Chang HH, Du J, Wu JF, Wang CY, Wang MH. Induction of renal 20-hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats. J Pharmacol Exp Ther 317: 11-18, 2006.
42. Zhou Y, Lin S, Chang HH, Du J, Dong Z, Dorrance AM, Brands MW, Wang MH. Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet. Am J Hypertens 18: 530-537, 2005. (Pubitemid 40502926)
43. Zhu Y, Usui HK, Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin Nephrol 27: 153-160, 2007. (Pubitemid 46553714)